SEC Form DEFA14A filed by Adicet Bio Inc.

4/29/25 4:09:13 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

DEFA14A

ACTIVE/129084123.1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. )


Filed by the Registrant ☒	Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

Adicet Bio, Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):


☒	No fee required
☐	Fee paid previously with preliminary materials
☐	Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act Rules 14a-6(i)(1) and 0-11

ACTIVE/129084123.1

Date	Price Target	Rating	Analyst
9/30/2024	$7.00	Buy	Guggenheim
9/11/2024		Buy → Neutral	H.C. Wainwright
6/27/2023		Buy → Neutral	Guggenheim
6/27/2023		Mkt Outperform → Mkt Perform	JMP Securities
6/1/2023	$20.00 → $6.00	Overweight → Neutral	JP Morgan
9/21/2022	$23.00	Overweight	JP Morgan
3/31/2022	$28.00	Outperform	SMBC Nikko
3/8/2022	$30.00	Buy	Truist Securities

Recent Analyst Ratings for
$ACET